Medtronic (MDT) heads into its Nov 24 fiscal Q2 report up 39.5% from its June 2 close: expectations, estimates, past report moves and momentum (Nov 15, 2026)
Published by Alexey Kovalyov, Founder, AstraEye Labs. Researched and written by its AI scientists.
Researched · Published
Introduction
Medtronic enters its November 24 report with uniformly bullish momentum and the stock sitting 10% above its 50-day average, yet analyst estimates for the quarter have barely moved in 30 days. That gap between what the price is pricing in and what the Street has formally endorsed is the central question heading into the print.
A median 3.12% earnings-day move on a stock already stretched above its averages means the report can either extend or sharply reverse the trend. Past reactions show MDT can move meaningfully on earnings day. At current levels, a downside move of that median size would still leave the stock well above its 50-day average, but a larger miss-driven reaction could test it. Against this: the most recent reaction, on September 1, was only 1.53%, well below the median.
Raised fiscal-year guidance from September anchors the bull case but also raises the bar for the upcoming print. By lifting organic revenue growth guidance to 7.25% to 7.75% and adjusted EPS to $5.94 to $6.00, Medtronic committed to an acceleration that the Q2 result must now corroborate or risk undermining. Against this: quarterly consensus revisions over 30 days are essentially zero, so the Street may already view the raised guide as fully reflected.
Findings
- MDT is likely to gap or move at least 2% on November 24, the day of its Q2 report, given its median past earnings-day move of 3.12% and the widened distance between price and estimates.Horizon: 11 days, to 26 November 2026
Why: Eight past reactions produced a 3.12% median move; the current gap between price momentum and flat revisions raises the stakes of the outcome.
What would change it: Pre-report guidance update or consensus shift.
- As of 15 November 2026, MDT is more likely to remain above its 50-day average through late November than to fall below it, absent a material earnings miss.Horizon: 14 days, to 29 November 2026
Why: The 10% premium to the 50-day average provides a buffer larger than the median earnings-day move of 3.12%, so only a severe reaction would breach it.
What would change it: Earnings miss or guidance cut.
- A median 3.12% earnings-day move on a stock already stretched above its averages means the report can either extend or sharply reverse the trend.
- Raised fiscal-year guidance from September anchors the bull case but also raises the bar for the upcoming print.
What would change this read
A meaningful consensus revision before November 24, a pre-announcement from Medtronic, or an earnings-day move larger than the 3.83% historical mean would shift the read on whether the rally is overextended or fundamentally supported.
ATLAS · Technical Readings
Bottom line
The momentum structure is cleanly bullish, but the 10% premium to the 50-day average and 18% premium to the 200-day average place MDT at the upper end of its own recent range heading into a binary event nine days away.
FELIX · Estimates and Guidance
Bottom line
Flat revisions alongside raised company guidance suggest the Street has absorbed the September guide lift without adding further upside to its models, leaving room for a surprise in either direction on the Q2 print.
NOVA · Earnings Surprise Record
Bottom line
The earnings surprise record holds no beat or miss determination for the latest release.
This desk published no bottom line, so its closing sentence stands in.
Questions and answers
Questions this research set out to answer
What revenue and earnings per share do analysts expect for the second quarter?
For the quarter ended October 30, analysts' consensus is EPS of 1.3344 and revenue of 9.48 billion dollars, as of November 15. Seven-day revisions to the quarter's consensus are zero on both measures.
What did Medtronic guide for the second quarter and the full fiscal year with its September 1 results?
With its September 1 results Medtronic raised fiscal 2027 guidance on two measures: organic revenue growth to 7.25% to 7.75%, up from a prior stated range of 6.75% to 7.25%, and adjusted diluted non-GAAP EPS to 5.94 to 6.00 dollars. No separate quarterly guidance is recorded in the evidence.
How have estimates for the quarter and the fiscal year moved over the past 30 days?
Over 30 days, fiscal-year EPS estimates moved minus 0.01% and revenue estimates moved 0.00%, producing a revision score of 49.9, rated as estimates broadly unchanged. Quarterly consensus revisions over 30 days were also near zero: EPS minus 0.01% and revenue minus 0.005%.
How large have the stock's moves after its past eight quarterly reports been?
Over eight past quarterly reports the median absolute earnings-day move is 3.12% and the mean is 3.83%. The median time to settle after a reaction is six sessions.
In which direction?
The three most recent reactions were plus 1.53% on September 1, plus 5.69% on June 3, and minus 3.1% on February 17.
Where does the price stand against its 20- and 50-day averages?
MDT closed 4.5% above its 20-day average and 10% above its 50-day average. Before the latest 1.85% session, the stock was roughly 8% above the 50-day average.
What do the momentum readings show?
The momentum label is bullish with all four voting indicators aligned: price above both the 20-day and 50-day averages, a positive MACD histogram, and RSI at 63.76 within the bullish band. No bearish or neutral votes are present.
Data sources
How these figures are produced and checked, the known limitations of this research, and how to report an error in it.
How this was computed
The analyses behind this report, each linked to its own public page.
One more analysis in this report is not in the public catalog, so its method is not listed here.
Follow and more research
Follow an asset in this report and AstraEye Labs emails you the link when its next public report is published. Free, with an account. Impersonal research, not investment advice.
Your own research
AstraEye runs AI research on the stocks and crypto assets you choose, and SAGE, its research guide, explains what it found. Your first research report is on us, and it can cover MDT: it starts as soon as you finish signing up, and the ticker goes on your watchlist.
Get a free research report on MDTEvery stock you name, before each of its announced reports, from $19 a month
Research on the trading day before each announced report date, and again on the next weekday morning once the session after the report has closed.
- Before: how far the stock moved after its past earnings reports, how long each move took to settle, and the Volatility Outlook. After: the move, set against the stock's own history.
- Free for one stock, by email and on the web. Space Analyst covers up to 25 stocks and adds the company's own guidance beside our estimate, what the news says, and each report to read in ChatGPT or Claude.
- The Volatility Outlook's weekly forecasts are recorded before the market opens, and the result is published on 17 May 2027, whatever it shows.
- Love it, or get your first payment back: 14 days, for any reason
- Stock research subscriptions that self-directed investors pay for elsewhere list at $199 to $299 a year (November 2026). Space Analyst is $190 a year, or $19 a month.
- Founding offer: the first 100 members to subscribe to Space Analyst monthly on the web with the code FOUNDING pay half price, $9.50 a month today, for as long as they stay subscribed. For new subscriptions; changing plans ends it.
Already use ChatGPT? AstraEye Labs is listed in its own app directory: install it there, then sign in to AstraEye when it asks.
Open AstraEye Labs in ChatGPTNew to reports like this one? The guide How to research U.S. stocks and crypto with AI: one real report, step by step walks through each part of one and how to check its numbers.
Researching a move of your own? The guide Why did a stock or coin move? How to research a big move with AI shows how to set it beside the market, the news and positioning from the same days.